logo

For the Inventor, By the Inventor

Inabe, Japan

Shoji Yokochi

This inventor holds 12 USPTO granted patents and 3 published patent applications and 3 EPO patents. Top assignees: Sanwa Kagaku Kenkyusho Co., Ltd., Telik, Inc., The University of Tokyo. Active years: 1999-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shoji Yokochi. Retrieved from https://idiyas.com/inventor/shoji-yokochi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 41.7

 

Average Co-Inventor Count = 9.3

ph-index = 3

Forward Citations = 34(Granted Patents)


Location History:

  • Nagoya, JP (1999)
  • Inabe-gun, JP (2003 - 2007)
  • Tokyo, JP (2020 - 2024)

Company Filing History:

goldMedal4 out of 108 
 
Sanwa Kagaku Kenkyusho Co., Ltd.
 patents
silverMedal4 out of 37 
 
Telik, Inc.
 patents
bronzeMedal4 out of 1,356 
 
The University of Tokyo
 patents
4. 2 out of 4 
 
Idac Theranostics, Inc.
 patents
5. 2 out of 575 
 
Ono Pharmaceutical Co., Ltd.
 patents
6. 2 out of 141 
 
Tokyo University of Science Foundation
 patents
7. 3 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 11919932 - HMGN partial peptide and cancer therapy using the same (2024-03-05),
2. 11572393 - HMGN partial peptide and cancer therapy using the same (2023-02-07),
3. 11168137 - Method for reducing side effects of immune checkpoint control agent (2021-11-09),
4. 10746726 - Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient (2020-08-18),
5. 7297696 - Antagonists of MCP-1 function and methods of use thereof (2007-11-20),
6. 6998407 - Antagonists of MCP-1 function and methods of use thereof (2006-02-14),
7. 6992086 - Antagonists of MCP-1 function and methods of use thereof (2006-01-31),
8. 6962926 - Antagonist of MCP-1 function, and compositions and methods of use thereof (2005-11-08),
9. 6809113 - Antagonists of MCP-1 function and methods of use thereof (2004-10-26),
10. 6677365 - Antagonists of MCP-1 function and methods of use thereof (2004-01-13),
11. 6670364 - Antagonists of MCP-1 function and methods of use thereof (2003-12-30),
12. 5869460 - Sulfated and phosphated saccharide derivatives, process for the (1999-02-09),

Title: The Innovative Contributions of Shoji Yokochi

Introduction

Shoji Yokochi is a prominent inventor based in Inabe-gun, Japan. He has made significant contributions to the field of cancer therapy, holding a total of 12 patents. His work focuses on developing novel therapeutic means that are effective and practical against cancer.

Latest Patents

One of Yokochi's latest patents involves HMGN partial peptides and their application in cancer therapy. This patent discloses a novel therapeutic means that includes peptides derived from a partial region of HMGN1, HMGN2, HMGN4, or HMGN5. These peptides serve as anti-cancer agents and effect enhancers, demonstrating an independent anti-tumor effect. Furthermore, they exhibit a remarkably excellent anti-tumor effect when used in combination with immune checkpoint regulators or anti-CD4 antibodies.

Career Highlights

Throughout his career, Shoji Yokochi has worked with notable companies such as Telik, Inc. and Sanwa Kagaku Kenkyusho Co., Ltd. His experience in these organizations has contributed to his expertise in the field of cancer research and therapy.

Collaborations

Yokochi has collaborated with esteemed colleagues, including Yoshiro Ishiwata and Kouji Matsushima. These partnerships have further enhanced his research and development efforts in innovative cancer treatments.

Conclusion

Shoji Yokochi's contributions to cancer therapy through his innovative patents and collaborations highlight his significant role in advancing medical science. His work continues to inspire future research in the field of oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…